Matthew Wanat to Medicare Part C
This is a "connection" page, showing publications Matthew Wanat has written about Medicare Part C.
Connection Strength
0.115
-
Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan; 25(1):63-70.
Score: 0.057
-
Group-based trajectory modeling to identify adherence patterns for direct oral anticoagulants in Medicare beneficiaries with atrial fibrillation: a real-world study on medication adherence. Int J Clin Pharm. 2024 Dec; 46(6):1525-1535.
Score: 0.057